IMG 0717 v2
IMG 0717 v2
23 Apr
Advocacy

Australian Trikafta Decision Deferred

23 April 2021

The Australian Pharmaceutical Benefits Committee (PBAC) has announced that it has deferred the listing of Trikafta on its Pharmaceutical Schedule (PBS) for people with CF aged 12 years and older with at least one copy of the F508del mutation.

PBAC considered that Trikafta provided a significant benefit for some patients who are homozygous for F508del and heterozygous for F508del with a minimal function mutation.  However, it deferred making a recommendation in order to allow for engagement with Vertex over the proposed listing, to address costs, financial implications, and risk-sharing in relation to currently listed CFTR modulators.

PBAC's deferral comes after more than 12 months of consideration, and approval for the use of Trikafta by the Australian Therapeutic Goods Administration (TGA).

Cystic Fibrosis NZ is very disappointed that Australians with CF and CF Australia did not get a resounding yes today.

But we know they won’t give up fighting and we look forward to a positive decision as soon as possible. 

 

More information: